Compare Piramal Healthcare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs VENUS REMEDIES - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES VENUS REMEDIES PIRAMAL ENTERPRISES/
VENUS REMEDIES
 
P/E (TTM) x 17.6 -1.0 - View Chart
P/BV x 1.1 0.1 1,550.0% View Chart
Dividend Yield % 1.6 0.0 -  

Financials

 PIRAMAL ENTERPRISES   VENUS REMEDIES
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
VENUS REMEDIES
Mar-18
PIRAMAL ENTERPRISES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs3,303126 2,623.2%   
Low Rs1,79761 2,940.8%   
Sales per share (Unadj.) Rs716.5301.8 237.4%  
Earnings per share (Unadj.) Rs79.7-24.9 -320.5%  
Cash flow per share (Unadj.) Rs107.92.5 4,240.5%  
Dividends per share (Unadj.) Rs28.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs1,477.5293.3 503.8%  
Shares outstanding (eoy) m184.4512.34 1,494.7%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.60.3 1,148.6%   
Avg P/E ratio x32.0-3.8 -850.9%  
P/CF ratio (eoy) x23.636.7 64.3%  
Price / Book Value ratio x1.70.3 541.3%  
Dividend payout %35.10-   
Avg Mkt Cap Rs m470,2921,154 40,760.6%   
No. of employees `0007.80.9 845.4%   
Total wages/salary Rs m22,504393 5,724.6%   
Avg. sales/employee Rs Th16,899.44,026.1 419.8%   
Avg. wages/employee Rs Th2,877.7425.0 677.1%   
Avg. net profit/employee Rs Th1,879.9-331.8 -566.6%   
INCOME DATA
Net Sales Rs m132,1533,724 3,548.6%  
Other income Rs m3,12823 13,902.2%   
Total revenues Rs m135,2813,747 3,610.8%   
Gross profit Rs m66,290395 16,790.7%  
Depreciation Rs m5,202338 1,537.5%   
Interest Rs m44,097354 12,446.3%   
Profit before tax Rs m20,119-275 -7,307.9%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,61132 27,250.9%   
Profit after tax Rs m14,701-307 -4,790.2%  
Gross profit margin %50.210.6 473.2%  
Effective tax rate %42.8-11.5 -372.9%   
Net profit margin %11.1-8.2 -135.0%  
BALANCE SHEET DATA
Current assets Rs m122,7422,638 4,653.4%   
Current liabilities Rs m310,8102,305 13,486.2%   
Net working cap to sales %-142.38.9 -1,591.4%  
Current ratio x0.41.1 34.5%  
Inventory Days Days23135 17.0%  
Debtors Days Days3946 83.8%  
Net fixed assets Rs m116,9044,871 2,400.1%   
Share capital Rs m369123 298.9%   
"Free" reserves Rs m272,1613,496 7,785.7%   
Net worth Rs m272,5303,619 7,530.3%   
Long term debt Rs m270,1961,374 19,659.2%   
Total assets Rs m856,2617,509 11,403.9%  
Interest coverage x1.50.2 653.1%   
Debt to equity ratio x1.00.4 261.1%  
Sales to assets ratio x0.20.5 31.1%   
Return on assets %6.90.6 1,087.8%  
Return on equity %5.4-8.5 -63.6%  
Return on capital %12.41.6 785.1%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m15,2000-   
Fx outflow Rs m4,889517 946.5%   
Net fx Rs m10,312-517 -1,996.4%   
CASH FLOW
From Operations Rs m-115,975514 -22,545.6%  
From Investments Rs m-8,265-123 6,714.1%  
From Financial Activity Rs m107,525-387 -27,777.0%  
Net Cashflow Rs m-16,6504 -396,433.3%  

Share Holding

Indian Promoters % 52.9 32.9 161.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 0.2 2,222.2%  
FIIs % 26.6 0.6 4,586.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 66.4 24.8%  
Shareholders   93,274 20,121 463.6%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 19, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS